Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Incyte Corporation - Common Stock
(NQ:
INCY
)
105.24
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Incyte Corporation - Common Stock
< Previous
1
2
...
19
20
21
22
23
24
25
26
Next >
Incyte to Present at Upcoming Investor Conference
May 24, 2022
From
Incyte
Via
Business Wire
CHMP Backs Approval of Lilly/Incyte's Olumiant For Patchy Hair Loss
↗
May 20, 2022
Via
Benzinga
Stock Market Rally Under Pressure As Walmart, Target Crash On Inflation Woes: Weekly Review
↗
May 20, 2022
A confirmed market uptrend is reeling as inflation's pain bites.
Via
Investor's Business Daily
Mizuho Sees Relief For This Small-Cap Stock After Patent Legal Overhang Lifted
↗
May 13, 2022
Via
Benzinga
Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas
↗
May 13, 2022
Key takeaways: Innovent Biologics terminated a plan to sell its bevacizumab biosimilar in North America with a local partner after trials for the drug fell behind schedule The...
Via
Benzinga
4 Analysts Have This to Say About Incyte
↗
May 04, 2022
Analysts have provided the following ratings for Incyte (NASDAQ:INCY) within the last quarter:
Via
Benzinga
Despite Q1 Earnings Miss, Incyte Shares Jump On Revised FY22 Sales Guidance
↗
May 03, 2022
Via
Benzinga
Incyte: Q1 Earnings Insights
↗
May 03, 2022
Incyte (NASDAQ:INCY) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Why Tech Leader Regeneron Shouldn't Sweat Its AbbVie Rival — For Now
↗
May 13, 2022
The race is on in eczema treatment as the biggest name faces new rivals.
Via
Investor's Business Daily
FDA Approves Lilly and Incyte's OLUMIANT (baricitinib) for Hospitalized Patients with COVID-19
↗
May 11, 2022
The U.S. Food and Drug Administration (FDA) has approved OLUMIANT® (baricitinib) for the treatment of COVID-19 in hospitalized patients.
Via
Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
↗
May 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Incyte Announces European Commission Approval of Jakavi® (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease
May 05, 2022
From
Incyte
Via
Business Wire
Incyte to Present at Upcoming Investor Conference
May 04, 2022
From
Incyte
Via
Business Wire
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
↗
May 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs
May 03, 2022
From
Incyte
Via
Business Wire
Global Cord Blood Enters Therapy Market Via Cellenkos Acquisition For Over $600M
↗
May 02, 2022
Global Cord Blood Corporation (NYSE: CO) will acquire Cellenkos Inc and the rights to develop and commercialize all of its existing and future products worldwide.
Via
Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
↗
May 02, 2022
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...
Via
Benzinga
3 Nasdaq Stocks to Buy Now for Growth
↗
May 01, 2022
These are the best Nasdaq stocks to invest in now. INCY, ROKU and FTXL can make great investments in the rest of the year.
Via
InvestorPlace
Incyte and Maruho Announce Strategic Alliance Agreement for Ruxolitinib Cream in Japan
April 28, 2022
From
Incyte
Via
Business Wire
EMA's Advisory Committee Backs Approval Of Incyte's Capmatinib In Advanced Lung Cancer Setting
↗
April 22, 2022
Via
Benzinga
Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta®) for the Treatment of METex14 Advanced Non-Small Cell Lung Cancer
April 22, 2022
From
Incyte
Via
Business Wire
How To Attend Incyte Q1 2022 Earnings Conference Call
↗
April 21, 2022
Incyte (NASDAQ:INCY) will host a conference call at 08:00 AM ET on May 3, 2022, to discuss Q1 2022 earnings results. How to Attend Incyte (INCY) Conference Call Follow this link to access the live...
Via
Benzinga
Incyte to Report First Quarter Financial Results
April 12, 2022
From
Incyte
Via
Business Wire
The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy
↗
April 06, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
This Favorable Sign Appears On Incyte's Chart
↗
April 05, 2022
If history is any guide, there may be good fortune ahead for shares of Incyte (NASDAQ:INCY). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the...
Via
Benzinga
Incyte's Ruxolitinib Shows Further Improvement In Facial, Total Body Re-pigmentation At 52 Weeks In Skin Disorder
↗
March 28, 2022
Incyte Corporation (NASDAQ: INCY)
Via
Benzinga
Incyte-Lilly's Olumiant Continue To Show Improved Scalp, Eyebrows, Eyelash Hair Regrowth At 52 Weeks
↗
March 28, 2022
At the American Academy of Dermatology Annual Meeting, Eli Lilly And Co (NYSE: LLY) and Incyte Corp (NASDAQ: INCY)
Via
Benzinga
Incyte Announces 52-Week Data From the Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients With Vitiligo
March 26, 2022
From
Incyte
Via
Business Wire
Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi®) for the Treatment of Acute and Chronic Graft-Versus-Host Disease
March 25, 2022
From
Incyte
Via
Business Wire
The Daily Biotech Pulse: Pfizer Reports Positive Ulcerative Colitis Study Data, Novavax COVID Shot Authorized For Adolescents In India, Argenx Stock Sale
↗
March 23, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
< Previous
1
2
...
19
20
21
22
23
24
25
26
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
